Spero Therapeutics (SPRO) Stock Statistics & Valuation Metrics

Spero Therapeutics has a market cap or net worth of $143.13M. The enterprise value is $103.80M.

Spero Therapeutics has 55,910,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Spero Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -112.93%.

The current PE Ratio of Spero Therapeutics is -0.81. Spero Therapeutics’s PEG ratio is 3.37.

In the last 12 months, Spero Therapeutics had revenue of 27.40M and earned -68.57M in profits. Earnings per share was -1.27.

In the last 12 months, operating cash flow was -33.38M and capital expenditures 0.00, giving a free cash flow of -33.38M billion.

Spero Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Spero Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Spero Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 11.71%

In the past 12 months, Spero Therapeutics has paid 0.00 in taxes.

Spero Therapeutics EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.30.

Spero Therapeutics has $48.89M in cash and marketable securities with $3.96M in debt, giving a net cash position of -$44.93M billion.

Gross margin is 83.07%, with operating margin of -267.78%, and net profit margin of -250.28%.

The average price target for Spero Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Hold